[ad_1] NEW YORK, Dec. 2, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of MediaAlpha, Inc. (“MediaAlpha” or the “Company”) (NYSE: MAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, […]

[ad_1] NEW YORK, Nov. 25, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of The Bancorp, Inc. (“Bancorp” or the “Company”) (NASDAQ: TBBK). Such investors are advised to contact Danielle Peyton at […]

[ad_1] NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. […]

[ad_1] NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton at [email protected] or […]

[ad_1] NEW YORK, Nov. 18, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of First Solar, Inc. (“First Solar” or the “Company”) (NASDAQ: FSLR).  Such investors are advised to contact Danielle […]